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Objectives:Our three academic institutions, Indiana University, NorthwesternMemorial Hospital, andWake
Forest, were among the ﬁrst in the United States to implement the Beckman Coulter AU5822 series chemistry
analyzers. We undertook this post-hoc multi-center study by merging our data to determine performance
characteristics and the impact of methodology changes on analyte measurement.
Design andmethods:We independently completed performance validation studies including precision, lin-
earity/analytical measurement range, method comparison, and reference range veriﬁcation. Complete data sets
were available from at least one institution for 66 analytes with the following groups: 51 from all three institu-
tions, and 15 from 1 or 2 institutions for a total sample size of 12,064.
Results: Precision was similar among institutions. Coefﬁcients of variation (CV) were b10% for 97%. Analytes
with CVs>10% included direct bilirubin and digoxin. All analytes exhibited linearity over the analyticalmeasure-
ment range. Method comparison data showed slopes between 0.900-1.100 for 87.9% of the analytes. Slopes for
amylase, tobramycin and urine amylase were b0.8; the slope for lipase was >1.5, due to known methodology
or standardization differences. Consequently, reference ranges of amylase, urine amylase and lipase required
only minor or no modiﬁcation.
Conclusion: The four AU5822 analyzers independently evaluated at three sites showed consistent precision,
linearity, and correlation results. Since installations, the test results had been well received by clinicians from all
three institutions.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Our three academic institutions, Indiana University (IU), Northwest-
ern Memorial Hospital (NMH), andWake Forest (WF), were among the
ﬁrst in the United States to adopt the Beckman Coulter AU5800 series
chemistry analyzers. The previous analyzer systems at all three institu-
tions were the Beckman Coulter Synchron DxC800 series. At each insti-
tution these analyzers were, on average, 5–7 years old and having
problems typical for such systems at the end of their useful life. In addi-
tion, during the timeframe that the DxC800 analyzers were in use, theake Forest School of Medicine,
, USA.
).
eering, PurdueUniversity,West
ciety of Clinical Chemists. Pubtest volume at each of the institutions had increased substantially. At
IU the annual volume of billable chemistry tests increased from 5.7 mil-
lion in 2005 to 7.9 million in 2012; at NMH the volume increased from
0.9 million (2005) to 1.2 million (2012); while at WF the volume in-
creased from 1.2 million (2007) to 1.5 million (2012). These increases
in test volume were predominantly due to expansion of the outreach
client base, addition of satellite draw sites and the acquisition or estab-
lishment of new afﬁliated hospitals. Moreover, given the increasing
pressures to contain healthcare cost, consolidation of testing also
added to the increased central core laboratory volume. At all three
institutions, specimens on which testing is not performed at outlying
locations are sent by courier to the main core laboratory where the
Beckman Coulter AU5822 analyzers and the robotic automation lines
are located. At IU four DxC800 analyzers were replaced by two
AU5822 and two AU680 analyzers. At NMH four DxC800 analyzers
were replaced by one AU5822 and two AU680 analyzers. At WF threelished by Elsevier Inc. This is an open access article under the CC BY license
882 M.K. Zimmerman et al. / Clinical Biochemistry 48 (2015) 881–885DxC800 analyzers were replaced by one AU5822 and two AU680 ana-
lyzers. At all three institutions the AU5822 analyzers are the primary
chemistry system in the highly automated core laboratory. The AU680
analyzers are used primarily as back-up systems and/or for low volume
testing. Other studies [1] have shown that results from the AU5822 and
AU680 analyzers are essentially equivalent. For our study all data are
from the core laboratories' primary analyzer, the AU5822.
Previously in our core laboratories the increase in specimen volume
had created a situation in which bottlenecks occurred even when all
DxC800 analyzers were running at or near capacity. The speed of the
DxC800 systemwas the rate-limiting factor. The theoretical throughput
for theDxC800 analyzer is 1440 tests/hwhile theAU5822 analyzer has a
theoretical throughput of 4000 photometric tests/h plus 1800 ion selec-
tive electrode (ISE) tests/h when equipped with the double ﬂow cell
modules [1]. Migration to the AU5822 system alongwith other changes
to the automated chemistry instrumentationmix and/or robotic lines at
each institution provides the needed throughput while also giving in-
creased capacity for future growth.
Switching to a new analyzer system, even from the same manu-
facturer, is a major undertaking for any laboratory. In this case, the
DxC800 and the AU5822 systems were developed and manufactured
by different R&D and Product Development teams, so they might be
expected to perform differently. In addition, the AU5822 system uses
differentmethodologies than the DxC800 for a number of analytes, pos-
sibly requiring modiﬁcation of the reference ranges. At each institution
we independently undertook a study to determine if the performance
characteristics of our newAU5822 systemswere comparable to our pre-
vious analyzers and to determine the impact of methodology changes
on analyte measurement including precision, linearity/analytical mea-
surement range (AMR), method comparison, and reference ranges.
Later we compared the data across multiple systems (n = 4) and mul-
tiple sites (n= 3). Single center or multi-center evaluations have previ-
ously been published [2–4], but our study is unique in that the
validation was performed without up-front collaboration and data
was only compared after the three individual studies had been complet-
ed. Most multi-center studies are planned and executed collaboratively
and often include sites that are related or geographically in proximity.
Our study included three independent institutions at diverse, wide-
spread geographic locations and provided a very large set of combined
data.
Materials and methods
Four AU5822 systems were installed by independent installation
teams at our three institutions. AU5822 systems for IU, NMH, andWF
are located within each institution's core lab, with IU having an
AU5822 on each of two adjacent but duplicated automation lines.
Validation studies including precision, linearity/AMR and method
comparison were conducted independently at each site as described
below. At each site, reference ranges were also veriﬁed for each ana-
lyte and compared to those for current methods. The data from all
sites were subsequently compared and consolidated for this multi-
center evaluation.
The AU5822 analyzers, the DxC800 analyzers, and most reagents
and calibrators were from Beckman Coulter (Brea, CA USA). TDM re-
agents and calibrators were from Siemens (Newark, DE USA). Quality
control materials were obtained from BioRad (Irvine, CA USA). Linearity
standard materials were from Verichem Laboratories (Providence, RI
USA) and Cliniqa LiniCAL TDM (Fisher Scientiﬁc, Houston, TX USA).
Validation studies
Validation studies were performed bymanufacturer representatives
and/or laboratory staff at each institution. These studies included preci-
sion, linearity/analytical measurement range (AMR), and method com-
parison correlating each institution's DxC800 and AU5822 analyzersusing EP Evaluator® software (Build 10.0.0.517, Data Innovations, LLC,
South Burlington, VT). Precision studies were performed according to
the CLSI EP05 protocol [5], using at least two levels of quality control
(QC) material. Precision was evaluated by analyzing 20 replicates of
each level of the quality control material and compiling the data for
analysis. To determine the linearity and AMR for each analyte, we per-
formed studies according to the CLSI EP06 protocol [6]. Depending on
the analyte being evaluated, 4 to 7 concentrations of linearity standards
material were used to evaluate linearity over the AMR. Triplicate mea-
surements were taken at each concentration spanning the analytical
range of the analyte as speciﬁed by the manufacturer. Method compar-
ison studieswere performed according to the CLSI EP09-A2 protocol [7].
For most analytes, a minimum of 20 to 40 patient specimens were in-
cluded at each institution for each analyte, as required by the protocol.
The range was from 12 (CRP by NMH) to 111 (ALP by IU). Additionally,
we consolidated method comparison data points frommultiple institu-
tions, and recalculated method comparison statistics based on the con-
solidated data set. For the 66 analytes studied, the total number of
specimens tested ranged from 40 for IgM to 342 for ALP with 58 assays
(87.9%) having more than 100 specimens and 27 assays (40.9%) having
more than 200 specimens in themerged data set. Specimens were ana-
lyzed on each of the two chemistry systems, the DxC800 and AU5822.
Deming regression was used to calculate slope, intercept and correla-
tion coefﬁcient (R) for each analyte at each site independently and
also for the larger merged data set.Reference ranges
Reference rangeswere established independently at each institution
using samples from 20 to 110 normal individuals, orwere veriﬁed using
samples from at least 20 individuals according to the protocols de-
scribed in CLSI EP28-A3 [8]. There were ten tests sets with less than
20 samples due to infrequent order. All individuals were presumptively
normal and the sampleswere de-identiﬁed prior to use. All studieswere
conducted in compliance with each institution's IRB policies.Compilation of data from all three institutions
WF and NMH contributed data from one AU5822 analyzer each; IU
contributed data from two analyzers (IU1 and IU2). The precision and
linearity/AMR data were tabulated. For themethod comparison studies,
the data from each institution were analyzed separately and then com-
bined for additional analysis with the exception of lactate which was
only analyzed separately for 2 institutions. Supplemental Table 4
showed the correlation and bias plots. The Deming regression line for
the combined data was calculated and plotted along with the 95% con-
ﬁdence limits.Results and discussion
Datawere available for 84 analytes at IU, 58 analytes at NMH, and 87
analytes atWF. Of these, complete data sets that included precision, lin-
earity/AMR, method comparison and reference ranges were available
from one or more institutions for 66 analytes. For these 66 analytes
being studied as a group, the specimen types included serum/plasma
for 53 analytes, urine for 12 analytes and CSF for 1 analyte, totalling
12,064. Of the 53 analytes using serum/plasma, 40 were chemistries
and the remaining 13 were drugs used for therapeutic drug monitoring
(TDM). For this paper we focused on those 66 analytes evaluated for all
elements of the study, i.e., precision, linearity/AMR, method compari-
son, and reference range at one or more of the institutions. At each
site the individual data were examined to ensure results were within
acceptable limits for that institution.
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Data from precision studies conducted at each of the three institu-
tions were collated to evaluate the combined precision at multiple ana-
lyte levels for the QC materials tested. Each precision set includes 20
data points. The precision data set for 66 analytes is available online as
Supplemental Table 1 measured assay precision.
For the 40 chemistries, CVs ranged from 0.0% to 14.6%, with 97.5%
having CVs ≤10% and 92.5% being ≤5%. The single precision outlier,
i.e., analyte with precision N10%, was Direct Bilirubin (DBIL) analyzed
in one data set on one system, IU#1 (mean 0.33, SD 0.05, CV 14.6%).
Overall, a total of 14 data sets were analyzed by all systems for DBIL.
The DBIL on IU#1 at Indiana University showed a CV of 14.6% for one
low level sample. The analyzer resulted 0.3 mg/dL 65% of the time and
0.4 mg/dL for the remaining 35% of the time. On a different low level
sample on the same IU instrument, 100% of the results gave 0.3 mg/dL.
These two precision evaluations were performed approximately 3
months apart.
For the 12 urine analytes, CVs ranged from 0.3% to 2.2%. All data sets
had CVs b5%. For the 13 therapeutic drugs (TDM), the precision CVs
ranged from 0.6% to 17.9%, with 92.3% being b10%. The precision outlier
(CV ≥10%)was digoxinwith 4 out of 14 data sets havingCVsN10%: IU#1
(mean 0.41, SD 0.04, CV 10.9%), IU#2 (mean 0.47, SD 0.09, CV 17.9% and
mean 0.61, SD 0.10, CV 16.1%) and WF (mean 0.45, SD 0.05, CV 11.4%).
For digoxin, a low level sample performed on IU#1 resulted 0.4 ng/mL
80% of the time. For the remaining 4 points, one point was resulted as
0.3 ng/dL, approximately −2.5 SD from the mean, and three points
(0.5 ng/dL) were approximately 2 SD from the mean. For IU#2, the 2
SD range for a low level sample was 0.42 to 0.81 ng/mL. Points 19
and 20 gave results of 0.9 ng/mL and 0.8 ng/mL respectively. For
the second low level sample performed on IU#2, the 2 SD range
was 0.30 to 0.65 ng/mL. The result for one point was 0.7 ng/mL. For
the remaining points, the results were 0.4 ng/mL, 0.5 ng/mL, and
0.6 ng/mL for 45%, 40%, and 10% of the time, respectively. CSF Glucose
was analyzed for precision at IU and WF, and had CVs ranging from
0% to 1.8% for 8 data sets. Interestingly, NMH had no analytes with
CVs ≥10%. For all analytes at three sites on four systems at all QC levels,
97% had CV ≤10% while 80.3% having CVs ≤5%.
A summary of the precision data for this study is shown in Table 1. In
comparison tomanufacturer's claims, 4 analytes—DBIL, TBIL, acetamin-
ophen, and digoxin showedCVs exceeding themanufacturer's claims by
2 .0–7.5%. Two analytes showed CVs N10%. — DBIL, 14.6% and digoxin,
17.9%, as compared to manufacturer's claims of b8% and b10.4%
respectively.
Linearity/AMR
For the 66 analytes studied all were found to be linear, as determined
using 4 to 7 concentrations of standards material that covered the AMR
speciﬁed by themanufacturer, andwithin allowable limits for each insti-
tution. Supplemental Table 2 showed the DxC and AU reference ranges
and AMRs. In comparison to manufacturer's claims, the upper limits of
the AMRs were within the claims: for HDLD, lactate, prealbumin and U
creatinine for 1 center, and for U Ca, U Mg, and U uric acid for 2 centers,
and greater than the claim for U amylase for 1 center.Table 1
Precision summary of assays on AU5800.
# Analytes # Data sets per Analyte
Chemistries 40 4–18
Urines 12 8–14
TDMs 13 11–15
CSF 1 8
Total 66 4–18Method comparison
Supplemental Table 3 showed the DxC 800 and AU5822 method
comparisons. For the 66 analytes, 63.6% utilized different methodolo-
gies: 21 of 40 serum/plasma chemistry analytes, and8 of 12urine chem-
istry analytes. All TDMs changed to EMIT methods while CSF Glucose
remained the same for both instruments. Even for methods with the
same methodology, the precise formulations may differ. Therefore, for
many analytes, a bias between instruments might result in different
slopes or intercepts. In these cases, new reference ranges might need
to be established as described in the reference ranges previously, or at
least the current reference ranges veriﬁed.
Deming regression, performed on data fromboth the individual sites
and the aggregate data, are shown in the Supplemental Table 4, showing
the correlation, bias plot and other statistics. Using the combined data
for the samples analyzed on both the DxC800 and AU5822 systems,
Deming regression showed 87.9% of the analytes with slopes between
0.900–1.100. Of the 19 chemistry analytes with unchangedmethodolo-
gy, Rs were N0.9735. Fig. 1 (c,d) showed the regression plots and statis-
tics for representative analytes albumin and BUN. For the chemistry
analytes with methodology changed between the DxC and AU plat-
forms, Rs for the aggregate data ranged between 0.9217 (Na) to
0.9998 (AST). Among the chemistry analytes, the most notable slope
changes were: amylase, which individually and when aggregated, had
decreased slopes b0.8, and lipase, which individually and when aggre-
gated had increased slopes N1.7, as shown by Fig. 1 (a,b). Urine amylase
also showed comparable slopes ≤0.8 for the individual and aggregated
data sets. Again, these changes were due to different methodologies.
IgG showed a decreased slope of 0.844, resulting in a minor change in
reference range.
Supplemental Table 4 showed that positive biases were evident for
GGT, UCa, and UCl, and negative biases for AST, C4 and CSF glucose,
and iron in one IU analyzer. Negative biaseswere observed for high con-
centrations of ALT, lactate andMg.With the exception of urine amylase,
Rs were ≥0.9930 for all urine analytes regardless of methodology
change. Urine amylase R, with methodology changes between ana-
lyzers, was 0.9856 in addition to a decreased slope.
For the AU5822 analyzer, the drug assay method was an EMIT,
homogeneous enzymatic immunoassay, while particle enhanced turbi-
dimetric inhibition immunoassayswere used in DxC. The exceptionwas
salicylate, utilizing salicylate hydroxylase. The aggregated drug assay
data showed some scatter around the regression lines. Rs were
≥0.9689 for all TDMs except digoxin (R = 0.9492). Digoxin's slope
was N1.1 for 2 analyzers, resulting in 1.135 for the combined data set.
As previously noted, tobramycin also showed a decreased slope of
0.733 with R = 0.9866. Table 2 summarized the correlation statistics
for those 8 analytes with slopes outside the range 0.900–1.100. These
are all tests with eithermethodology (e.g., amylase, lipase) or standard-
ization (e.g., tobramycin) differences between the DxC800 and AU5822
instruments and those results were expected.
Reference ranges
For most of the 66 analytes studied, the reference ranges at each
institution needed only minor or no adjustments. In some cases, noCV range (%) ≤5% CV ≤10% CV
0.0–14.6 37 (92.5%) 39 (97.5%)
0.3–2.2 12 (100%) 12 (100%)
0.6–17.9 3 (23.1%) 12 (92.3%)
0.0–1.8 1 (100%) 1 (100%)
0.0–17.9 53 (80.3%) 64 (97.0%)
a) Amylase 
c) Albumin
IU1 IU2 NMH WF All
Mean (DxC) 100.1250 100.1250 91.9500 76.6765 93.3592
Mean (AU5800) 79.2568 71.5227 69.1250 54.6324 69.5373
R 0.9994 0.9974 0.9969 0.9985 0.9965
N 88 88 40 68 284
Slope 0,783 0.702 0.704 0.720 0.741
Intercept 0.809 1.256 4.412 0.537 0.368
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Fig. 1.Method correlation plots and statistics for selected assays. Fig. 1a amylase and b lipase are examples of analyte correlations that required modiﬁcations to reference ranges due to
expected differences in methodology or standardization. Fig. 1c albumin and d ALT are examples of the many analytes that showed good correlation and did not require modiﬁcations to
reference ranges.
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gy. This can be attributed to the common standardization and trace-
ability schemes used by the developers. The exceptions were those
analytes that showed slopes beyond 0.900–1.100 between platforms.Table 2
Analytes with method comparison slopes b0.9 or N1.1.
Analyte Slope Intercept R
Amylase 0.741 0.368 0.9965
CRP 1.293 −0.253 0.9912
IgG 0.844 113.169 0.9960
Lipase 1.874 −24.766 0.9600
U-Amylase 0.763 −3.661 0.9856
Amikacin 0.883 0.535 0.9933
Digoxin 1.135 0.051 0.9492
Tobramycin 0.733 0.144 0.9866These included serum amylase and lipase, and urine lipase in NMH
that required reference range changes. Urine amylase was changed in
NMH but not in IU. Tobramycin also showed slope difference but the
reference range was not changed. With aminoglycosides such as
tobramycin, the clinical concern is two-fold, treating the infection
with concurrent signs of patient improvement and avoiding ototoxicity
whenever possible. Reference ranges for these analytes, as established
on the DxC and AU platforms, at each institution are shown in Table 3.
Reference Range data for all 66 analytes both on Synchron DxC and on
AU5800 are shown in the online Supplemental Table 2.
Limitations included the comparison studies not performed on the
same sample sets. They were collected at different time period with
possible different patient demographic. As previously noted, the study
was conceptualized after the validation studies were completed.
As shown by the above sections, we compared the precision, AMR,
and reference interval results to the manufacturer's claims in the
Table 3
Reference ranges for analytes, listed in Table 2, with differing methodology and slopes.
Analyte Site DxC reference range AU reference range Reference range change
Amylase IU 25–161 U/L 19–86 U/L Yes
NMH 20–115 U/L 29–103 U/L Yes
WF 30–122 U/L 29–103 U/L Yes
Lipase IU 22–51 U/L 7–59 U/L Yes
NMH 7–60 U/L 11–82 U/L Yes
WF 20–50 U/L 11–82 U/L Yes
Urine–amylase IU 1–17 (U/L)/h 1–17 (U/L)/h No
NMH 1–17 (U/L)/h 5–27 (U/L)/h Yes
WF NA NA NA
Tobramycin IU TR = 0.0–2.0 μ g/mL
PK = 4.0–10.0 μ g/mL
TR = 0.0–2.0 μ g/mL
PK = 4.0–10.0 μ g/mL
No
NMH TR = b2.0 μ g/mL
PK = 5.0–10.0 μ g/mL
TR = b2.0 μ g/mL
PK = 5.0–10.0 μ g/mL
No
WF 5.0–80.0 μ g/mL 10.0–30.0 μ g/mL Yes
885M.K. Zimmerman et al. / Clinical Biochemistry 48 (2015) 881–885Instructions for Use. All the AMRs met the claims though Supplemental
Table 2 shows some minor differences, based on variations in testing
and in local implementations. Reference intervals were similarly vali-
dated though again with some differences in local implementation
and within the institution's policies on changes of reference intervals.
Precision data shown in Supplemental Table 1 in general were well
within the claims with minor differences. Apparent exceptions for
high CVs for DBIL and TBIL are actually within the SD claims for low
analyte levels. Other precision exceptions with apparent high CVs for
lithium, acetaminophen, digoxin, and tobramycin are all instances of a
single QC level at a single institution showing a high CV but with an
acceptable SD at a low analyte concentration and that were not repro-
ducible at other sites. The analytes with well-established and clinically
relevant performance criteria were well accepted by clinicians in all
three institutions.
Conclusions
Four AU5822 analyzers independently evaluated at three separate
institutions provided consistent results for precision, linearity/analytical
measurement range, method comparison and reference ranges such
that the data could be merged for aggregate analysis. The merged data
of 12,064 samples provided a substantially larger data set than those
of previously published studies. A total of 66 analytes, each with at
least one site providing all elements of the performance data, were in-
cluded in our study. Precision CVs were b10% for almost all analytes
studied and themajority of linearity/AMRs werewithin the limits spec-
iﬁed by themanufacturer and established by the individual laboratories
separately. Deming regression analysis on the aggregate data set
showed that 87.9% of the analytes studied had slopes of 0.900–1.100.
Slopes outside this range were found for 6 analytes with changes in
methodology or standardization between the instruments, and for 2
analytes with no change in methodology or standardization. Changes
in methodology required changes in reference ranges at all sites for 2
analytes, amylase and lipase, as was not unexpected. Many analytes,
however, despite methodology change, only required minor or no ad-
justments. When there was no methodology change, the DxC and AU
platforms yielded similar results.
This largemulti-center study demonstrates that the AU5822 analyz-
er offered very consistent results among individual laboratories even ingeographically separated locations with diverse patient populations.
We also concluded that, despitemethodology or standardization chang-
es on the AU5822 analyzer relative to the Synchron DxC, the impact of
changing analyzers in our laboratories created few challenges while
allowing us to update and enhance our analytical and workﬂow pro-
cesses. Since installations, the test results had been well received by
clinicians from all three institutions.
Supplementary data to this article can be found online at http://dx.
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